EFFICACY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE, TYROSINE KINASE 2 INHIBITOR, IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS AND PRIOR EXPOSURE TO BIOLOGIC THERAPY: SUBANALYSIS FROM THE PHASE 2 LATTICE-UC STUDY

Stefan Schreiber  1     Nicholas Powell  2     Florian Rieder  3     Anita Afzali  4     Yi Luo  5     Mark T. Osterman  5     Chun Wu  5     Lisu Wang  5     Courtney Radosti  5     Aditya Patel  5    
1 University Hospital Schleswig-Holstein, Kiel, Germany
2 Imperial College London, London, United Kingdom
3 Digestive Diseases and Surgery Institute Cleveland Clinic, Cleveland, United States
4 The Ohio State University Inflammatory Bowel Disease Center and Division of Gastroenterology, Hepatology, and Nutrition, Columbus, United States
5 Bristol Myers Squibb, Princeton, United States

Topic
IBD, Nurses, Primary Care

Conference
UEG Week 2022

Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Social Sharing